A 32-week, Monocentric, Exploratory, Single Arm Study to Assess Immune Function and MRI Disease Activity in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Transferred from Previous Treatment with Natalizumab to Gilenya® (Fingolimod) (ToFingo-Successor)
Grunddaten zu diesem Projekt
Art des Projektes: Eigenmittelprojekt
Laufzeit an der Universität Münster: 01.01.2014 - 30.06.2016